Euro devices industry ponders issue of self-regulation: is there more change to come?
This article was originally published in Clinica
Executive Summary
How will the regulation of medical devices change over the next ten years? Is there enough flexibility in the system to allow for a greater degree of self-regulation? Are notified bodies really needed? These were among the issues at a medical device industry networking organised by the IQA in London on April 6. Amanda Maxwell reports
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.